World journal of urology · 2010
Impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kohjimoto Yasuo, Iba Akinori, Shintani Yasuyo, Inagaki Takeshi, Uekado Yasunari, Hara Isao
Аннотация
OBJECTIVES: To determine the impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer (NMIBC).
METHODS: This study examined 491 patients treated with transurethral resection and/or intravesical bacillus Calmette-Guerin (BCG) therapy for primary NMIBC at our institution between 1985 and 2005. The patients' age at treatment was classified into categories of younger than 50, 50-59, 60-69, 70-79, and 80 years or older. Recurrence-free survival and progression-free survival were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models.
RESULTS: Tumors of broad-based, multiple, and higher grades were more frequent with increasing patient age. Intravesical BCG therapy was less frequently performed on elderly patients. At a median follow-up of 45 months, patients 80 years or older had the lowest recurrence-free survival and progression-free survival among the age groups (log-rank P < 0.001 and P = 0.019, respectively). On Cox proportional hazard model, age was an independent risk factor for tumor recurrence and progression after controlling for all confounding variables. The recurrence risk was 2.3 times higher for patients 80 years or older than those aged 60-69 years (P < 0.001).
CONCLUSIONS: Older age adversely affected the outcome of patients with NMIBC, which is particularly apparent in patients 80 years or older. Further prospective studies to confirm these findings are warranted.
METHODS: This study examined 491 patients treated with transurethral resection and/or intravesical bacillus Calmette-Guerin (BCG) therapy for primary NMIBC at our institution between 1985 and 2005. The patients' age at treatment was classified into categories of younger than 50, 50-59, 60-69, 70-79, and 80 years or older. Recurrence-free survival and progression-free survival were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models.
RESULTS: Tumors of broad-based, multiple, and higher grades were more frequent with increasing patient age. Intravesical BCG therapy was less frequently performed on elderly patients. At a median follow-up of 45 months, patients 80 years or older had the lowest recurrence-free survival and progression-free survival among the age groups (log-rank P < 0.001 and P = 0.019, respectively). On Cox proportional hazard model, age was an independent risk factor for tumor recurrence and progression after controlling for all confounding variables. The recurrence risk was 2.3 times higher for patients 80 years or older than those aged 60-69 years (P < 0.001).
CONCLUSIONS: Older age adversely affected the outcome of patients with NMIBC, which is particularly apparent in patients 80 years or older. Further prospective studies to confirm these findings are warranted.
Предметные рубрики MeSH
Administration, IntravesicalAdultAge DistributionAgedAged, 80 and overBCG VaccineCarcinoma, PapillaryCombined Modality TherapyFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMuscle, SmoothNeoplasm InvasivenessNeoplasm Recurrence, LocalProportional Hazards ModelsUrinary BladderUrinary Bladder NeoplasmsUrologic Surgical ProceduresYoung Adult